Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65

-- FNAIT Natural History Study to Inform Frequency of FNAIT Risk in a Broad and Diverse Population of Pregnant Women ---- Study Designed to Provide a Contemporary Control Dataset to Support a Future Registrational Trial in Pregnant Women --NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a cli...

Related Keywords

New York ,United States ,United Kingdom ,California ,Netherlands ,Connecticut ,San Diego ,New Haven ,Norway ,Germany ,Sweden ,American ,Hannah Deresiewicz ,Alloimmune Thrombocytopenia ,Jorge Gaeta ,Emilie Vander Haar ,Exchange Commission ,American Society Of Hematology ,Stern Investor Relations Inc ,Rallybio Corporation Nasdaq ,Linkedin ,Twitter ,History Study ,Inform Frequency ,Diverse Population ,Contemporary Control Dataset ,Future Registrational Trial ,Rallybio Corporation ,Rallybio Fetal ,Neonatal Alloimmune Thrombocytopenia ,American Society ,Annual Meeting ,Weill Cornell Medicine ,New York Presbyterian Hospital ,Technology Incubation Program ,Quarterly Report ,Investor Relations ,